U.S. Markets closed

Wilex AG (WL6.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
2.629+0.007 (+0.267%)
At close: 5:36PM CEST
Full screen
Previous Close2.622
Open2.629
Bid0.000 x 57300
Ask0.000 x 225000
Day's Range2.629 - 2.629
52 Week Range1.449 - 3.390
Volume1,100
Avg. Volume6,689
Market Cap39.16M
BetaN/A
PE Ratio (TTM)-4.54
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • WILEX AG :WL6-DE: Earnings Analysis: Q2, 2017 By the Numbers : July 18, 2017
    Capital Cubelast month

    WILEX AG :WL6-DE: Earnings Analysis: Q2, 2017 By the Numbers : July 18, 2017

    Categories: Yahoo FinanceGet free summary analysis WILEX AG reports financial results for the quarter ended May 31, 2017. Highlights Summary numbers: Revenues of EUR 0.38 million, Net Earnings of EUR -2.29 million. Gross margins narrowed from 50.02% to 27.43% compared to the same period last year, operating (EBITDA) margins now -586.68% from -507.00%. Change in operating cash ... Read more (Read more...)

  • WILEX AG :WL6-DE: Earnings Analysis: Q1, 2017 By the Numbers : April 20, 2017
    Capital Cube4 months ago

    WILEX AG :WL6-DE: Earnings Analysis: Q1, 2017 By the Numbers : April 20, 2017

    Categories: Yahoo FinanceGet free summary analysis WILEX AG reports financial results for the quarter ended February 28, 2017. Highlights Summary numbers: Revenues of EUR 0.45 million, Net Earnings of EUR -1.96 million. Change in operating cash flow of -80.39% compared to same period last year is about the same as change in earnings, likely no significant movement ... Read more (Read more...)

  • Reuters6 months ago

    Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment

    "We talk a lot with companies, and as the data improves and the company develops, the more interest we have, that's for sure," chief executive officer Luigi Costa told Reuters. Nanovector is currently preparing a final test phase for its Betalutin drug candidate, a treatment for Non-Hodgkin Lymphoma (NHL) designed to attach itself to tumours in a novel way before killing them with a dose of radiation.